New figures from the BioIndustry Association (BIA) show UK biotech financing showed signs of recovery in the first quarter of 2026.
The data shows that the growth was driven by a rebound in venture capital investment and a broader distribution of funding across companies and stages.
Investor confidence grows
In Q1 2026, total equity financing in the UK biotech sector reached £552m, up from £466m in Q4 2025.
The BIA attributed this growth to venture capital, which increased from 17% to £516m, reflecting rising investor confidence.
While still below the £924m reported in Q1 2025 (though this was skewed by a few mega-rounds), Q1 2026 showed a more balanced distribution of investment across a wider range of companies and stages.
Deal activity rose significantly, with 25 transactions, a 67% year-on-year increase, indicating a more active funding environment. The UK also secured 57% of all European biotech venture capital this quarter.
Overall, the data reflects a shift towards a more balanced funding landscape, with later-stage rounds capturing the largest share of capital and early-stage activity also strengthening.
M&A activity invigorates the sector
The BIA also noted that M&A activity was a standout feature of the quarter.
High‑profile acquisitions, including Eli Lilly's £4.6bn purchase of Centessa Pharmaceuticals and Amgen’s £ 626m acquisition of Dark Blue Therapeutics, reinforced UK-origin assets as must-haves for international pipelines.
The BIA added that, despite the narrow public market window, this data shows that the strategic value of UK companies is being affirmed.
Jane Wall, Managing Director of BIA, said: "It comes as great relief to see those green shoots that started showing at the end of 2025 grow into a more sustained and healthier shift in market dynamics in the first quarter of 2026."
While headline figures often fluctuate based on the presence of a few megadeals, the underlying story of Q1 is one of accelerating momentum and a broader distribution of capital across the UK’s innovative ecosystem.
"As we move further into 2026, the architecture for growth is building with strong political support."
"With deal flow broadening and international interest in our world-class ecosystem high, now is the time to ensure that domestic capital follows the lead of our global peers to fully unlock the value of UK innovation and that the Government delivers its broader commitments through the Life Sciences Sector Plan."